Activist Investor Beretta Launches Proxy Contest, Nominates Directors, Opposes Share Increase
Summary
Activist investor Beretta Holding S.A., Sturm, Ruger & Co.'s largest shareholder, has formally launched a proxy contest to elect four independent directors and is urging shareholders to vote against the company's proposals to increase authorized shares and approve executive compensation, citing severe underperformance and entrenched leadership.
Key Events
-
Proxy Contest Launched
Beretta Holding S.A., the largest shareholder, formally launched a proxy contest to elect four independent directors to Sturm, Ruger & Co.'s nine-member Board at the upcoming Annual Meeting.
-
Opposition to Share Increase
Beretta recommends shareholders vote against the company's proposal to increase authorized shares from 40 million to 60 million, arguing there is no immediate need and questioning management's judgment.
-
Executive Compensation Challenged
The activist urges a vote against the advisory "say-on-pay" proposal, criticizing "poorly aligned compensation structures" and the company's sustained operational underperformance.
-
Performance Under Scrutiny
Beretta highlights a "prolonged period of operational underperformance and strategic stagnation," including a 90%+ decline in net income and significant margin compression, attributing it to the current board's "entrenched" leadership.
Analysis
This filing marks a significant escalation in the ongoing hostile proxy battle between Sturm, Ruger & Co. and its largest shareholder, Beretta Holding S.A. Beretta is directly challenging the incumbent board by nominating four independent directors and actively campaigning against key company proposals, including a substantial increase in authorized shares and the advisory vote on executive compensation. The activist's detailed critique of the company's "prolonged period of operational underperformance," including a 90%+ decline in net income and significant margin compression, underscores the high stakes of this contest. The Board's prior rejection of Beretta's tender offer and refusal to waive the poison pill further highlight the deep divisions. The outcome of this proxy fight could fundamentally alter the company's strategic direction, governance, and capital structure, making it a critical event for investors.
At the time of this filing, RGR was trading at $40.63 on NYSE in the Manufacturing sector, with a market capitalization of approximately $647.8M. The 52-week trading range was $28.33 to $48.21. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.